{
    "id": 28147,
    "fullName": "TMB low",
    "impact": "",
    "proteinEffect": "",
    "geneVariantDescriptions": [
        {
            "description": "TMB low indicates a low tumor mutational burden.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 999999991,
        "geneSymbol": "TMB",
        "terms": [
            "TMB",
            "Tumor Mutational Burden"
        ]
    },
    "variant": "low",
    "createDate": "05/03/2018",
    "updateDate": "05/03/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14021,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (BERIL-1) trial, Buparlisib (BKM120) and Taxol (paclitaxel) combination treatment resulted in improved overall survival in head and neck squamous cell carcinoma patients with low tumor mutational burden (HR=0.57) (PMID: 29490986; NCT01852292).",
            "molecularProfile": {
                "id": 29717,
                "profileName": "TMB low"
            },
            "therapy": {
                "id": 1545,
                "therapyName": "Buparlisib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11417,
                    "pubMedId": 29490986,
                    "title": "Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29490986"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14127,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Pegilodecakin (AM0010) and Keytruda (pembrolizumab) (n=5) or Opdivo (nivolumab) (n=29) combination therapy resulted in partial response in 62.5% (5/8) of patients with non-small cell lung carcinoma who tested low to intermediate for tumor mutational burden (TMB) (J Clin Oncol 36, 2018 (suppl; abstr 9018); NCT02009449).",
            "molecularProfile": {
                "id": 29717,
                "profileName": "TMB low"
            },
            "therapy": {
                "id": 6820,
                "therapyName": "Nivolumab + Pegilodecakin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11471,
                    "pubMedId": null,
                    "title": "Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.",
                    "url": "https://meetinglibrary.asco.org/record/160279/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14126,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Pegilodecakin (AM0010) and Keytruda (pembrolizumab) (n=5) or Opdivo (nivolumab) (n=29) combination therapy resulted in partial response in 62.5% (5/8) of patients with non-small cell lung carcinoma who tested low to intermediate for tumor mutational burden (TMB) (J Clin Oncol 36, 2018 (suppl; abstr 9018); NCT02009449).",
            "molecularProfile": {
                "id": 29717,
                "profileName": "TMB low"
            },
            "therapy": {
                "id": 6770,
                "therapyName": "Pegilodecakin + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11471,
                    "pubMedId": null,
                    "title": "Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.",
                    "url": "https://meetinglibrary.asco.org/record/160279/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15032,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with gastroesophageal junction adenocarcinoma with Mdm2 amplification, low tumor mutational burden, and MSI stable, had hyperprogression after treatment with Opdivo (nivolumab) (PMID: 30148248).",
            "molecularProfile": {
                "id": 30606,
                "profileName": "MDM2 amp MSI low TMB low"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12407,
                    "pubMedId": 30148248,
                    "title": "Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30148248"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15950,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung carcinoma patients with low or intermediate tumor mutational burden (<2.83 mutations/Mb or 2.84-4.85 mutations/Mb) harboring either EGFR exon 19 deletion or EGFR L858R demonstrated a longer time to therapy discontinuation and greater overall survival compared to patients with high tumor mutational burden (>4.85 mutations/Mb) when treated with either Tarceva (erlotinib) or Gilotrif (afatinib) (PMID: 30045933).",
            "molecularProfile": {
                "id": 31338,
                "profileName": "EGFR exon 19 del TMB low"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14072,
                    "pubMedId": 30045933,
                    "title": "Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045933"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15953,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung carcinoma patients with low or intermediate tumor mutational burden (< 2.83 mutations/Mb or 2.84-4.85 mutations/Mb) harboring either EGFR exon 19 deletion or EGFR L858R demonstrated a longer time to therapy discontinuation and greater overall survival compared to patients with high tumor mutational burden (>4.85 mutations/Mb) when treated with either Tarceva (erlotinib) or Gilotrif (afatinib) (PMID: 30045933).",
            "molecularProfile": {
                "id": 31338,
                "profileName": "EGFR exon 19 del TMB low"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14072,
                    "pubMedId": 30045933,
                    "title": "Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045933"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15951,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung carcinoma patients with low or intermediate tumor mutational burden (< 2.83 mutations/Mb or 2.84-4.85 mutations/Mb) harboring either EGFR exon 19 deletion or EGFR L858R demonstrated a longer time to therapy discontinuation and greater overall survival compared to patients with high tumor mutational burden (>4.85 mutations/Mb) when treated with either Tarceva (erlotinib) or Gilotrif (afatinib) (PMID: 30045933).",
            "molecularProfile": {
                "id": 31340,
                "profileName": "EGFR L858R TMB low"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14072,
                    "pubMedId": 30045933,
                    "title": "Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045933"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15952,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung carcinoma patients with low or intermediate tumor mutational burden (< 2.83 mutations/Mb or 2.84-4.85 mutations/Mb) harboring either EGFR exon 19 deletion or EGFR L858R demonstrated a longer time to therapy discontinuation and greater overall survival compared to patients with high tumor mutational burden (>4.85 mutations/Mb) when treated with either Tarceva (erlotinib) or Gilotrif (afatinib) (PMID: 30045933).",
            "molecularProfile": {
                "id": 31340,
                "profileName": "EGFR L858R TMB low"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14072,
                    "pubMedId": 30045933,
                    "title": "Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045933"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17729,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, patients with TMB low and CD274 (PD-L1)-negative advanced gastric cancer (n=33) demonstrated worse objective response rate (3.0% vs 33.3%), progression-free survival (1.9 vs 2.7 months), and overall survival (4 vs 12.1 months) compared to patients with TMB high or CD274 (PD-L1)-positive tumors (n=18) in response to Toripalimab (JS001) treatment (PMID: 31236579; NCT02915432).",
            "molecularProfile": {
                "id": 32762,
                "profileName": "CD274 neg TMB low"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15752,
                    "pubMedId": 31236579,
                    "title": "Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236579"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20440,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COMBI-AD) trial, Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy compared to placebo resulted in more benefit (HR=0.49, p<0.0001) in TMB low patients with resected melanoma harboring BRAF V600E or V600K, than in TMB high (HR=0.75, p=0.27) patients, however, TMB was not associated with relapse-free survival in the combination treatment group (PMID: 32007138; NCT01682083).",
            "molecularProfile": {
                "id": 35176,
                "profileName": "BRAF V600E TMB low"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17843,
                    "pubMedId": 32007138,
                    "title": "Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32007138"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20441,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COMBI-AD) trial, Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy compared to placebo resulted in more benefit (HR=0.49, p<0.0001) in TMB low patients with resected melanoma harboring BRAF V600E or V600K, than in TMB high (HR=0.75, p=0.27) patients, however, TMB was not associated with relapse-free survival in the combination treatment group (PMID: 32007138; NCT01682083).",
            "molecularProfile": {
                "id": 35177,
                "profileName": "BRAF V600K TMB low"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17843,
                    "pubMedId": 32007138,
                    "title": "Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32007138"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29717,
            "profileName": "TMB low",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30606,
            "profileName": "MDM2 amp MSI low TMB low",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31338,
            "profileName": "EGFR exon 19 del TMB low",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31340,
            "profileName": "EGFR L858R TMB low",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32762,
            "profileName": "CD274 neg TMB low",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35176,
            "profileName": "BRAF V600E TMB low",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35177,
            "profileName": "BRAF V600K TMB low",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}